Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SGNT's Cash to Debt is ranked higher than
98% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. SGNT: No Debt )
SGNT' s 10-Year Cash to Debt Range
Min: 0.96   Max: No Debt
Current: No Debt

Equity to Asset 0.80
SGNT's Equity to Asset is ranked higher than
87% of the 754 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. SGNT: 0.80 )
SGNT' s 10-Year Equity to Asset Range
Min: -1.15   Max: 0.82
Current: 0.8

-1.15
0.82
Interest Coverage 16.87
SGNT's Interest Coverage is ranked higher than
60% of the 488 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.25 vs. SGNT: 16.87 )
SGNT' s 10-Year Interest Coverage Range
Min: 16.87   Max: 9999.99
Current: 16.87

16.87
9999.99
F-Score: 7
Z-Score: 11.52
M-Score: -2.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 6.80
SGNT's Operating margin (%) is ranked higher than
70% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.92 vs. SGNT: 6.80 )
SGNT' s 10-Year Operating margin (%) Range
Min: -258.05   Max: 12.82
Current: 6.8

-258.05
12.82
Net-margin (%) 5.50
SGNT's Net-margin (%) is ranked higher than
71% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.26 vs. SGNT: 5.50 )
SGNT' s 10-Year Net-margin (%) Range
Min: -253.66   Max: 12.09
Current: 5.5

-253.66
12.09
ROE (%) 6.55
SGNT's ROE (%) is ranked higher than
74% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.33 vs. SGNT: 6.55 )
SGNT' s 10-Year ROE (%) Range
Min: -26.08   Max: 16.09
Current: 6.55

-26.08
16.09
ROA (%) 4.98
SGNT's ROA (%) is ranked higher than
78% of the 814 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.07 vs. SGNT: 4.98 )
SGNT' s 10-Year ROA (%) Range
Min: -52.59   Max: 12.27
Current: 4.98

-52.59
12.27
ROC (Joel Greenblatt) (%) 20.21
SGNT's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.20 vs. SGNT: 20.21 )
SGNT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -442.09   Max: 48.06
Current: 20.21

-442.09
48.06
Revenue Growth (%) -40.00
SGNT's Revenue Growth (%) is ranked lower than
52% of the 655 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. SGNT: -40.00 )
SGNT' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 46.4
Current: -40

0
46.4
» SGNT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

SGNT Guru Trades in Q3 2013

Jim Simons 56,600 sh (+454.9%)
Steven Cohen 24,130 sh (+369.82%)
» More
Q4 2013

SGNT Guru Trades in Q4 2013

NWQ Managers 675,935 sh (New)
Joel Greenblatt 39,358 sh (New)
Jim Simons 98,500 sh (+74.03%)
Steven Cohen Sold Out
» More
Q1 2014

SGNT Guru Trades in Q1 2014

Steven Cohen 142,700 sh (New)
NWQ Managers 855,750 sh (+26.6%)
Jim Simons Sold Out
Joel Greenblatt 21,573 sh (-45.19%)
» More
Q2 2014

SGNT Guru Trades in Q2 2014

Paul Tudor Jones 18,200 sh (New)
Joel Greenblatt Sold Out
NWQ Managers 802,021 sh (-6.28%)
» More
» Details

Insider Trades

Latest Guru Trades with SGNT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Sold Out 0.01%$19.73 - $25.51 $ 32.3846%0
Joel Greenblatt 2014-03-31 Reduce -45.19%0.01%$18 - $25.38 $ 32.3848%21573
Joel Greenblatt 2013-12-31 New Buy0.02%$20.25 - $25.39 $ 32.3844%39358
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 38.10
SGNT's P/E(ttm) is ranked higher than
78% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.30 vs. SGNT: 38.10 )
SGNT' s 10-Year P/E(ttm) Range
Min: 18.76   Max: 473.95
Current: 38.1

18.76
473.95
P/B 4.20
SGNT's P/B is ranked higher than
68% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.39 vs. SGNT: 4.20 )
SGNT' s 10-Year P/B Range
Min: 2.49   Max: 5.06
Current: 4.2

2.49
5.06
P/S 3.90
SGNT's P/S is ranked higher than
72% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.81 vs. SGNT: 3.90 )
SGNT' s 10-Year P/S Range
Min: 0.46   Max: 3.74
Current: 3.9

0.46
3.74
PFCF 30.70
SGNT's PFCF is ranked higher than
91% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SGNT: 30.70 )
SGNT' s 10-Year PFCF Range
Min: 13.15   Max: 69.27
Current: 30.7

13.15
69.27
EV-to-EBIT 30.62
SGNT's EV-to-EBIT is ranked higher than
77% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.17 vs. SGNT: 30.62 )
SGNT' s 10-Year EV-to-EBIT Range
Min: 15.1   Max: 331.9
Current: 30.62

15.1
331.9
Current Ratio 4.65
SGNT's Current Ratio is ranked higher than
86% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. SGNT: 4.65 )
SGNT' s 10-Year Current Ratio Range
Min: 1.57   Max: 4.65
Current: 4.65

1.57
4.65
Quick Ratio 3.74
SGNT's Quick Ratio is ranked higher than
86% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. SGNT: 3.74 )
SGNT' s 10-Year Quick Ratio Range
Min: 0.89   Max: 3.74
Current: 3.74

0.89
3.74

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.40
SGNT's Price/Net Cash is ranked higher than
92% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SGNT: 12.40 )
SGNT' s 10-Year Price/Net Cash Range
Min: 7.42   Max: 116.56
Current: 12.4

7.42
116.56
Price/Net Current Asset Value 7.81
SGNT's Price/Net Current Asset Value is ranked higher than
90% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SGNT: 7.81 )
SGNT' s 10-Year Price/Net Current Asset Value Range
Min: 4.77   Max: 12.72
Current: 7.81

4.77
12.72
Price/Tangible Book 4.39
SGNT's Price/Tangible Book is ranked higher than
74% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. SGNT: 4.39 )
SGNT' s 10-Year Price/Tangible Book Range
Min: 2.6   Max: 5
Current: 4.39

2.6
5
Price/Median PS Value 1.50
SGNT's Price/Median PS Value is ranked higher than
66% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.27 vs. SGNT: 1.50 )
SGNT' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 1.23
Current: 1.5

0.24
1.23
Price/Graham Number 2.80
SGNT's Price/Graham Number is ranked higher than
80% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.82 vs. SGNT: 2.80 )
SGNT' s 10-Year Price/Graham Number Range
Min: 1.6   Max: 7.66
Current: 2.8

1.6
7.66
Earnings Yield (Greenblatt) 3.30
SGNT's Earnings Yield (Greenblatt) is ranked higher than
68% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.90 vs. SGNT: 3.30 )
SGNT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 6.6
Current: 3.3

0.3
6.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:S06.Germany
Sagent Pharmaceuticals Co is a pharmaceutical company engaged in developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.
» More Articles for SGNT

Headlines

Articles On GuruFocus.com
No related article found.

More From Our Partners
Sagent Pharmaceuticals Announces Acquisition of Omega Laboratories Oct 1 2014 - BENZINGA

More From Other Websites
Sagent Pharmaceuticals Announces Acquisition of Omega Laboratories Oct 01 2014
4:10 pm Sagent Pharma announces acquisition of Omega Laboratories; expected to be immediately... Oct 01 2014
Akorn Upgraded On Strong Generic Drug Trends Sep 29 2014
Sagent Pharmaceuticals Announces the Launch of GLYDO(TM) (Lidocaine HCI Jelly USP, 2%) Sep 26 2014
Sagent Pharmaceuticals Announces the Introduction of Oxaliplatin Injection, USP Sep 23 2014
Sagent Pharmaceuticals Announces the Launch of Ketorolac Tromethamine Injection, USP Sep 17 2014
Sagent Pharmaceuticals Announces the Launch of Ibandronate Sodium Injection Sep 05 2014
SAGENT PHARMACEUTICALS, INC. Financials Aug 12 2014
SAGENT PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Aug 05 2014
Sagent Pharmaceuticals Announces the Reintroduction of Irinotecan Hydrochloride Injection, USP Aug 05 2014
5 Drug Companies Profiting From Generics Aug 04 2014
Sagent Pharma downgraded by Needham Jul 31 2014
SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 30 2014
Q2 2014 SAGENT Pharmaceuticals Inc Earnings Release - Before Market Open Jul 30 2014
Sagent Pharmaceuticals Reports Second Quarter 2014 Financial Results Jul 30 2014
UPDATE: Bank Of America Downgrades Sagent Pharmaceuticals On Potential Near-Term Volatility Jul 25 2014
UPDATE: Sagent Pharmaceuticals Sets Date and Time for Release of Second Quarter 2014 Financial... Jul 17 2014
Sagent Pharmaceuticals Sets Date and Time for Release of Second Quarter 2014 Financial Results Jul 17 2014
Can the Rally in Sagent Pharmaceuticals (SGNT) Shares Continue? Jul 07 2014
Moving Average Crossover Alert: Sagent (SGNT) Jul 01 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK